Caplacizumab is used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, in combination with plasma exchange and immunosuppressive therapy; it is the first approved drug targeting von Willebrand factor (vWF) to inhibit microthrombus formation in aTTP by blocking the interaction between vWF and platelets.